Literature DB >> 26453202

Semisynthesis and Enzymatic Preparation of Post-translationally Modified α-Synuclein.

Bruno Fauvet1, Hilal A Lashuel2,3.   

Abstract

Posttranslational modifications (PTMs) serve as molecular switches for regulating protein folding, function, and interactome and have been implicated in the misfolding and amyloid formation by several proteins linked to neurodegenerative diseases, including Alzheimer's and Parkinson's disease. Understanding the role of individual PTMs in protein misfolding and aggregation requires the preparation of site-specifically modified proteins, as well as the identification of the enzymes involved in regulating these PTMs. Recently, our group has pioneered the development of enzymatic, synthetic, and semisynthetic strategies that allow site-specific introduction of PTMs at single or multiple sites and generation of modified proteins in milligram quantities. In this chapter, we provide detailed description of enzymatic and semisynthetic strategies for the generation of the phosphorylated α-Synuclein (α-Syn) at S129, (pS129), which has been identified as a pathological hallmark of Parkinson's disease. The semisynthetic method described for generation of α-Syn-pS129 requires expertise with protein chemical ligation, but can be used to incorporate other PTMs (single or multiple) within the α-Syn C-terminus if desired. On the other hand, the in vitro kinase-mediated phosphorylation strategy does not require any special setup and is rather easy to apply, but its application is restricted to the generation of α-Syn_pS129. These methods have the potential to increase the availability of pure and homogenous modified α-Syn reagents, which may be used as standards in numerous applications, including the search for potential biomarkers of synucleinopathies.

Entities:  

Keywords:  Alpha-synuclein; Amyloid; Desulfurization; Native chemical ligation; Parkinson’s disease; Phosphorylation; Posttranslation modification; Semisynthesis

Mesh:

Substances:

Year:  2016        PMID: 26453202     DOI: 10.1007/978-1-4939-2978-8_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

Review 1.  Chemoenzymatic Semisynthesis of Proteins.

Authors:  Robert E Thompson; Tom W Muir
Journal:  Chem Rev       Date:  2019-11-27       Impact factor: 60.622

2.  Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity.

Authors:  Hilal A Lashuel; Anne-Laure Mahul-Mellier; Salvatore Novello; Ramanath Narayana Hegde; Yllza Jasiqi; Melek Firat Altay; Sonia Donzelli; Sean M DeGuire; Ritwik Burai; Pedro Magalhães; Anass Chiki; Jonathan Ricci; Manel Boussouf; Ahmed Sadek; Erik Stoops; Christian Iseli; Nicolas Guex
Journal:  NPJ Parkinsons Dis       Date:  2022-10-20

3.  The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease.

Authors:  Rita Machado de Oliveira; Hugo Vicente Miranda; Laetitia Francelle; Raquel Pinho; Éva M Szegö; Renato Martinho; Francesca Munari; Diana F Lázaro; Sébastien Moniot; Patrícia Guerreiro; Luis Fonseca-Ornelas; Zrinka Marijanovic; Pedro Antas; Ellen Gerhardt; Francisco Javier Enguita; Bruno Fauvet; Deborah Penque; Teresa Faria Pais; Qiang Tong; Stefan Becker; Sebastian Kügler; Hilal Ahmed Lashuel; Clemens Steegborn; Markus Zweckstetter; Tiago Fleming Outeiro
Journal:  PLoS Biol       Date:  2017-03-03       Impact factor: 8.029

Review 4.  Looking at the recent advances in understanding α-synuclein and its aggregation through the proteoform prism.

Authors:  Vladimir N Uversky
Journal:  F1000Res       Date:  2017-04-20

Review 5.  Ubiquitin and Parkinson's disease through the looking glass of genetics.

Authors:  Helen Walden; Miratul M K Muqit
Journal:  Biochem J       Date:  2017-04-13       Impact factor: 3.857

Review 6.  Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies.

Authors:  Pedro Magalhães; Hilal A Lashuel
Journal:  NPJ Parkinsons Dis       Date:  2022-07-22

7.  Comparative Analysis of Total Alpha-Synuclein (αSYN) Immunoassays Reveals That They Do Not Capture the Diversity of Modified αSYN Proteoforms.

Authors:  Lara Petricca; Nour Chiki; Layane Hanna-El-Daher; Lorène Aeschbach; Ritwik Burai; Erik Stoops; Mohamed-Bilal Fares; Hilal A Lashuel
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 8.  Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease.

Authors:  Luis M A Oliveira; Thomas Gasser; Robert Edwards; Markus Zweckstetter; Ronald Melki; Leonidas Stefanis; Hilal A Lashuel; David Sulzer; Kostas Vekrellis; Glenda M Halliday; Julianna J Tomlinson; Michael Schlossmacher; Poul Henning Jensen; Julia Schulze-Hentrich; Olaf Riess; Warren D Hirst; Omar El-Agnaf; Brit Mollenhauer; Peter Lansbury; Tiago F Outeiro
Journal:  NPJ Parkinsons Dis       Date:  2021-07-26

9.  Phospho-S129 Alpha-Synuclein Is Present in Human Plasma but Not in Cerebrospinal Fluid as Determined by an Ultrasensitive Immunoassay.

Authors:  Cristina Cariulo; Paola Martufi; Margherita Verani; Lucia Azzollini; Giordana Bruni; Andreas Weiss; Sean M Deguire; Hilal A Lashuel; Eugenia Scaricamazza; Giulia Maria Sancesario; Tommaso Schirinzi; Nicola Biagio Mercuri; Giuseppe Sancesario; Andrea Caricasole; Lara Petricca
Journal:  Front Neurosci       Date:  2019-08-22       Impact factor: 4.677

10.  Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson's disease.

Authors:  Shengnan Zhang; Yu-Qing Liu; Chunyu Jia; Yeh-Jun Lim; Guoqin Feng; Enquan Xu; Houfang Long; Yasuyoshi Kimura; Youqi Tao; Chunyu Zhao; Chuchu Wang; Zhenying Liu; Jin-Jian Hu; Meng-Rong Ma; Zhijun Liu; Lin Jiang; Dan Li; Renxiao Wang; Valina L Dawson; Ted M Dawson; Yan-Mei Li; Xiaobo Mao; Cong Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-29       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.